Jeffrey Weber, MD, PhD, of the Perlmutter Cancer Center, New York, NY, talks about his presentation based on the Novartis PLATforM trial, aiming to test three arms of combination treatments using the spartalizumab antibody in a PD-1 refractory population. Dr Weber notes that results from clinical trials testing these combinations will play a key role in the future implementation of definite trials. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.